Brind.
  1. LIXTE Biotechnology Holdings, Inc. has announced recent scientific developments regarding its drug candidates, including inhibitors targeting protein phosphatase 2A.

LIXTE's compound is being studied in collaboration with Roche and GlaxoSmithKline.

3 reports, 1 independent Updated Aug 25
Gone quiet
Reports
3
Developments
1
Repetition
67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

LIXTE's compound is being studied in collaboration with Roche and GlaxoSmithKline.

Who's involved

What this event is mainly about
Hoffmann-La RocheGlaxoSmithKline

Keep exploring

Part of

LIXTE Biotechnology Holdings, Inc. has announced recent scientific developments regarding its drug candidates, including inhibitors targeting protein phosphatase 2A. All 2 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswire24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets Current Clinical Trial Focus is MSS Colorectal Cancer, Ovarian Clear-Cell Carcinoma, and Soft-Tissue Sarcoma DENVER, Aug. 25, 2025 (GLOBE
  • GlobeNewswireLIXTE Biotechnology Holdings Provides Corporate Update -Completes Two Financings, Raising $6.5 Million- -Regains Compliance for Continued Listing on Nasdaq- -Announces Management Changes; Adds Two Ne
  • GlobeNewswire24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025 Breakthrough Protein Phosphatase 2A inhibitor LB-100 Targets Ovarian Clear